Our press release publishing policy can be accessed here.
844-857, Subhani, Mohsan, et al
GLP-1 drugs show promise for weight management Across the reviews, tirzepatide, semaglutide, and liraglutide each led to significant weight loss compared to placebo after one to two years, with these effects likely to be sustained while treatment continues
Keep a log of your weight history, blood pressure readings, and lab results from the past 6 to 12 months
Depending on the drug, it may also lower cardiovascular risk or the likelihood of kidney complications in those with type 2 diabetes, ease heart failure symptoms, reduce liver fat, improve metabolic dysfunction, and lessen the severity of sleep apnea